Advisory Research’s CRISPR Therapeutics CRSP Stock Holding History

Advisory Research’s Portfolio CRSP Stock Details CRSP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	–	Sell	-5,560	Closed	-$348K	–	195
2023 Q4	$348K	Buy	+5,560	New	+$307K	0.05%	278
2021 Q3	–	Sell	-3,201	Closed	-$518K	–	368
2021 Q2	$518K	Buy	+3,201	New	+$389K	0.03%	261
2021 Q1	–	Sell	-7,444	Closed	-$1.14M	–	351
2020 Q4	$1.14M	Sell	7,444 -6,171	-45%	-$729K	0.08%	177
2020 Q3	$1.14M	Sell	13,615 -930	-6%	-$82.5K	0.11%	163
2020 Q2	$1.07M	Buy	+14,545	New	+$850K	0.1%	165

Other funds holding CRSP

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return

NAMA

Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

NMC

NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Advisory Research's CRSP Position: Q1 2024 in Review

Advisory Research sold out of CRISPR Therapeutics (CRSP) in Q1 2024, closing a stake of 5,560 shares — an estimated $348K sold.

Advisory Research first reported a position in CRSP in Q2 2020 and held it in 5 quarters. The position peaked at $1.14M in Q4 2020. 484 funds tracked by Wall St. Rank hold CRSP as of Q1 2024.

Advisory Research reported no remaining CRISPR Therapeutics position as of Q1 2024 after selling out during the quarter.
Advisory Research sold 5,560 CRISPR Therapeutics shares in Q1 2024, an estimated $348K.
Advisory Research first reported a position in CRISPR Therapeutics in Q2 2020 and held it in 5 quarters.
Advisory Research's CRISPR Therapeutics position peaked at $1.14M in Q4 2020.
484 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q1 2024.

Based on Advisory Research's 13F filing for Q1 2024, filed 14 May 2024.